Literature DB >> 8842448

Cardiac and gastric effects of histamine H2 receptor antagonists: no evidence for a correlation between lipophilicity and receptor affinity.

G Coruzzi1, M Adami, C Pozzoli, F Giorgi, G Bertaccini.   

Abstract

1. A series of histamine H2 receptor antagonists with different lipophilicity were tested in cardiac and gastric assays in order to reveal possible differences in receptor affinity. Lipophilicity of the compounds was expressed as CLOG P (theoretically-determined logarithm of octanol:water partition coefficient) and log k' (logarithm of capacity factor, experimentally-determined by reverse-phase high performance liquid chromatography). 2. Aminopotentidine (APT) and iodoaminopotentidine (I-APT), which are both lipophilic compounds, behaved as insurmountable antagonists of histamine responses in rat isolated gastric fundus (pKB = 6.20 +/- 0.16 and 6.89 +/- 0.19, respectively) and guinea-pig isolated papillary muscle (pKB = 6.34 +/- 0.37 and 6.81 +/- 0.26, respectively). They were approximately as effective as ranitidine (RAN) in reducing histamine-induced acid secretion in the anaesthetized rat, ID50 values being 0.018 +/- 0.02, 0.020 +/- 0.03 and 0.036 +/- 0.01 mumol kg-1 i.v. for APT, I-APT and RAN, respectively. Both APT and I-APT had a significantly longer duration of action than RAN. 3. The hydrophilic compound, SK&F 92857, was inactive up to 10 microM in modifying histamine-induced acid secretion in the isolated rat stomach. In the papillary muscle, low concentrations (0.1-1 microM) of this compound produced a competitive antagonism of the histamine responses (pA2 value = 7.38 +/- 0.11), while a higher concentration (10 microM) significantly reduced the maximal response to histamine. 4. RAN competitively antagonized histamine effects with a comparable affinity in cardiac and gastric preparations (pA2 values were 6.42 +/- 0.09 and 6.78 +/- 0.38 in heart and stomach, respectively). 5. Results obtained in this study clearly showed that the discrepancies between gastric and cardiac effects observed for some H2 antagonists are not explained solely by differences in lipophilicity of compounds. Moreover, the significant correlation found between CLOG P and log k' parameter, which takes into account, besides their lipophilicity, the ionization of the molecules, suggests that ionization has a similar influence for all the molecules on the partition between the lipophilic and aqueous phase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842448      PMCID: PMC1909814          DOI: 10.1111/j.1476-5381.1996.tb15608.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Correlation between log POCT/H2O and pKB estimates for a series of muscarinic and histamine H2-receptor antagonists.

Authors:  N P Shankley; J W Black; C R Ganellin; R C Mitchell
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

2.  Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.

Authors:  R C Young; R C Mitchell; T H Brown; C R Ganellin; R Griffiths; M Jones; K K Rana; D Saunders; I R Smith; N E Sore
Journal:  J Med Chem       Date:  1988-03       Impact factor: 7.446

Review 3.  Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model.

Authors:  M J Robertson; I G Dougall; D Harper; K C McKechnie; P Leff
Journal:  Trends Pharmacol Sci       Date:  1994-10       Impact factor: 14.819

4.  Synthesis and in vitro pharmacology of arpromidine and related phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs.

Authors:  A Buschauer
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

5.  Synthesis and histamine H2-receptor antagonist activity of 4-(1-pyrazolyl)butanamides, guanidinopyrazoles, and related compounds.

Authors:  A Buschauer; R Mohr; W Schunack
Journal:  Arch Pharm (Weinheim)       Date:  1995-04       Impact factor: 3.751

6.  Pharmacological characterization and autoradiographic localization of histamine H2 receptors in human brain identified with [125I]iodoaminopotentidine.

Authors:  E Traiffort; H Pollard; J Moreau; M Ruat; J C Schwartz; M I Martinez-Mir; J M Palacios
Journal:  J Neurochem       Date:  1992-07       Impact factor: 5.372

7.  Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.

Authors:  M J Robertson; J C Barnes; G M Drew; K L Clark; F H Marshall; A Michel; D Middlemiss; B C Ross; D Scopes; M D Dowle
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

8.  Reversible and irreversible labeling and autoradiographic localization of the cerebral histamine H2 receptor using [125I]iodinated probes.

Authors:  M Ruat; E Traiffort; M L Bouthenet; J C Schwartz; J Hirschfeld; A Buschauer; W Schunack
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

9.  Zolantidine (SK&F 95282) is a potent selective brain-penetrating histamine H2-receptor antagonist.

Authors:  C R Calcutt; C R Ganellin; R Griffiths; B K Leigh; J P Maguire; R C Mitchell; M E Mylek; M E Parsons; I R Smith; R C Young
Journal:  Br J Pharmacol       Date:  1988-01       Impact factor: 8.739

10.  Activity of the new histamine H2-receptor antagonist zolantidine at cardiac and gastric H2-receptors.

Authors:  G Coruzzi; M Adami; C Pozzoli; E Poli; G Bertaccini
Journal:  Pharmacology       Date:  1994-02       Impact factor: 2.547

View more
  2 in total

1.  Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2).

Authors:  Y H Han; Y Kato; M Haramura; M Ohta; H Matsuoka; Y Sugiyama
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

2.  Saturable absorptive transport of the hydrophilic organic cation ranitidine in Caco-2 cells: role of pH-dependent organic cation uptake system and P-glycoprotein.

Authors:  David L Bourdet; Dhiren R Thakker
Journal:  Pharm Res       Date:  2006-06-08       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.